NCT05088343

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Adult Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Effect of hetrombopag on the pharmacokinetics of rosuvastatin in healthy subjects.

Detailed description

The primary objective of the study is to evaluate the effect of hetrombopag on pharmacokinetics of healthy Chinese adult subjects after oral administration of rosuvastatin calcium tablets. The secondary objective of the study is to evaluate the safety of rosuvastatin alone and when co-administered with hetrombopag.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Rosuvastatin	Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
DRUG	Hetrombopag	7.5 mg hetrombopag was administered on Day 6 to Day 11.

Timeline

• Start date: 2020-09-07
• Primary completion: 2021-01-16
• Completion: 2021-01-16
• First posted: 2021-10-21
• Last updated: 2021-10-21

Locations

1 site across 1 country: China